Rossitto Cristiano, Gueli Alletti Salvatore, Rotolo Stefano, Cianci Stefano, Panico Giovanni, Scambia Giovanni
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy.
Eur J Obstet Gynecol Reprod Biol. 2016 Aug;203:132-5. doi: 10.1016/j.ejogrb.2016.05.007. Epub 2016 May 20.
The evolution of minimally invasive surgery has moved beyond reduction of surgical trauma while maintaining adequate efficacy and safety standards. Percuvance™ Percutaneous Surgical System (PSS) instruments represents the last novelty in this panorama. Consisting of less than 3mm laparoscopic shaft introduced percutaneously with an interchangeable 5mm tool installed in place of the needle tip, they combine micro-invasiveness and operative performance.
We prospectively collected and retrospectively analyzed data of 10 cases of laparoscopic total hysterectomy with Percuvance™ PSS for benign or early malignant gynecological diseases in order to assess the capability and safety of this new device. Data were recorded in a prospectively designed clinical database including patient demographics characteristics, operative data, intra- and postoperative complications, conversion rate, length of hospital stay and cosmetic outcome.
The reported series consisted of 10 patients undergoing total laparoscopic hysterectomy with a median age of 51.5 years (range 44-72 years) and a median BMI (body mass index) of 25.3 (range 19.7-30.4). All patients had bilateral salpingo-oophorectomy or bilateral salpingectomy and two of them underwent pelvic lymphadenectomy. A median operative time of 67min (range 45-180min) and a median estimated blood loss (EBL) of 50ml (range 10-100ml) were registered. Median PSS introduction time was 5min (range 3-10min). No conversions to standard laparoscopy or laparotomy were required and no intraoperative complications occurred. Discharge was on day 1 in 4 cases, on day 2 in the other 6 cases. All patients conveyed complete satisfaction with the cosmetic result and postoperative pain control. No complications were registered within 30 days after surgery.
PSS total laparoscopic hysterectomy is safe and feasible with good results in terms of operative time, cosmesis, postoperative pain, recovery and short hospitalization. Further studies are needed to compare PSS total hysterectomy to conventional multi-access laparoscopic and other mini-invasive approaches.
微创手术的发展已超越了在保持足够疗效和安全标准的同时减少手术创伤的范畴。Percuvance™经皮手术系统(PSS)器械代表了这一领域的最新创新。该器械经皮引入的腹腔镜轴直径小于3mm,针尖端处安装有可互换的5mm工具,兼具微创性和手术性能。
我们前瞻性收集并回顾性分析了10例使用Percuvance™ PSS进行腹腔镜全子宫切除术治疗良性或早期恶性妇科疾病的病例数据,以评估这种新器械的性能和安全性。数据记录在一个前瞻性设计的临床数据库中,包括患者人口统计学特征、手术数据、术中和术后并发症、中转率、住院时间和美容效果。
所报告的系列包括10例行全腹腔镜子宫切除术的患者,中位年龄51.5岁(范围44 - 72岁),中位体重指数(BMI)为25.3(范围19.7 - 30.4)。所有患者均行双侧输卵管卵巢切除术或双侧输卵管切除术,其中2例接受了盆腔淋巴结清扫术。记录的中位手术时间为67分钟(范围45 - 180分钟),中位估计失血量(EBL)为50ml(范围10 - 100ml)。PSS引入的中位时间为5分钟(范围3 - 10分钟)。无需转为标准腹腔镜手术或开腹手术,术中未发生并发症。4例患者于术后第1天出院,另外6例于术后第2天出院。所有患者对美容效果和术后疼痛控制均表示完全满意。术后30天内未发生并发症。
PSS全腹腔镜子宫切除术安全可行,在手术时间、美容效果、术后疼痛、恢复情况及住院时间短等方面效果良好。需要进一步研究将PSS全子宫切除术与传统多通道腹腔镜手术及其他微创方法进行比较。